Related Experiment Video
Updated: May 8, 2026
Anterior High-Resolution Optical Coherence Tomography in the Diagnosis and Therapeutic Monitoring of Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
Sorafenib induced eruptive melanocytic lesions
Abstract:
Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepatocellular carcinoma. Dermatologic side effects include hand-foot skin reaction, facial and scalp erythema and desquamation, splinter subungual hemorrhages, alopecia, pruritus, xerosis, keratoacanthomas, and squamous cell carcinomas. We report sudden eruption of melanocytic nevi diffusely in a patient receiving sorafenib.
Insights
Sorafenib, a cancer drug, can cause skin issues. A patient experienced a sudden, widespread outbreak of moles while taking sorafenib.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Sorafenib is an FDA-approved multikinase inhibitor used for advanced renal cell carcinoma and hepatocellular carcinoma.
- Known dermatologic side effects of sorafenib include hand-foot skin reaction, erythema, desquamation, alopecia, and squamous cell carcinomas.
Observation:
- A patient undergoing sorafenib treatment presented with an unexpected dermatologic finding.
- The patient exhibited a sudden and diffuse eruption of melanocytic nevi.
Findings:
- The occurrence of sudden, widespread melanocytic nevi eruption is a previously unreported side effect of sorafenib.
- This finding expands the spectrum of known cutaneous adverse events associated with sorafenib therapy.
Implications:
- This case highlights the importance of monitoring for uncommon dermatologic side effects during sorafenib treatment.
- Further investigation may be warranted to understand the mechanism behind sorafenib-induced melanocytic nevi.
- Clinicians should be aware of this potential adverse reaction when prescribing sorafenib.
